<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3166">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04326725</url>
  </required_header>
  <id_info>
    <org_study_id>2020-2/1</org_study_id>
    <nct_id>NCT04326725</nct_id>
  </id_info>
  <brief_title>Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia</brief_title>
  <official_title>Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istinye University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istinye University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthcare professionals mainly doctors, nurses and their first degree relatives (spouse,
      father, mother, sister, brother, child) who have been started hydroxychloroquine(plaquenil)
      200mg single dose repeated every three weeks plus vitaminC including zinc once a day were
      included in the study. Study has conducted on 20th of march. Main purpose of the study was to
      cover participants those who are facing or treating COVID19 infected patients in Ankara.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthcare professionals mainly doctors, nurses and their first degree relatives (spouse,
      father, mother, sister, brother, child) who have been started hydroxychloroquine(plaquenil)
      200mg single dose repeated every three weeks plus vitaminC including zinc once a day were
      included in the study. Study has conducted on 20th of march. Main purpose of the study was to
      cover participants those who are facing or treating COVID19 infected patients.PArticipants,
      age, sex, BMI, smoking history, comorbid disease were also registered.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 20, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Protection against COVID-19</measure>
    <time_frame>4 months</time_frame>
    <description>persons who took this medication should not have an infection</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pneumonitis</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <description>Subjects with prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plaquenil 200Mg Tablet</intervention_name>
    <description>health workers under risk who took this medications</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <other_name>Redoxan</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Mainly doctors, nurses, health workers in the hospital whereby they have close contacts
        with possile COVID-19 infected patients were included. Their first degree relatives(spouse,
        child, parents)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. person who are working as health professional with contact to known COVID positive
             case

          2. Their first degree relatives (child, spouse or parents)

          3. must be able to swallow tablets

        Exclusion Criteria:

          1. Already using plaquenil for other reasons (RA etc)

          2. person with the diagnosis of COVID infection

          3. Person with the condition may cause complications with this medication (severe CVD, av
             block, already has ophtalmological complications, organ failure of any degree etc).

          4. Documented allergic history to chloroquine;

          5. Documented history of hematological system diseases;

          6. Documented history of chronic liver and kidney diseases;

          7. Documented history of cardiac arrhythmia or chronic heart diseases;

          8. Documented history of retina or hearing dysfunction;

          9. Documented history of mental illnesses; 10. Use of digitalis due to the previous
             disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahir M Ozmen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istinye University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istinye University Medical School</name>
      <address>
        <city>Istanbul</city>
        <zip>34010</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020 Apr;55(4):105932. doi: 10.1016/j.ijantimicag.2020.105932. Epub 2020 Mar 4.</citation>
    <PMID>32145363</PMID>
  </reference>
  <reference>
    <citation>Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 May;55(5):105938. doi: 10.1016/j.ijantimicag.2020.105938. Epub 2020 Mar 12.</citation>
    <PMID>32171740</PMID>
  </reference>
  <reference>
    <citation>Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Jun;57:279-283. doi: 10.1016/j.jcrc.2020.03.005. Epub 2020 Mar 10.</citation>
    <PMID>32173110</PMID>
  </reference>
  <reference>
    <citation>Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.</citation>
    <PMID>32074550</PMID>
  </reference>
  <reference>
    <citation>Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60. doi: 10.5582/ddt.2020.01012.</citation>
    <PMID>32147628</PMID>
  </reference>
  <reference>
    <citation>Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res. 2020 Jan 31;9:72. doi: 10.12688/f1000research.22211.2. eCollection 2020. Review.</citation>
    <PMID>32117569</PMID>
  </reference>
  <reference>
    <citation>Song P, Karako T. COVID-19: Real-time dissemination of scientific information to fight a public health emergency of international concern. Biosci Trends. 2020 Mar 16;14(1):1-2. doi: 10.5582/bst.2020.01056. Epub 2020 Feb 25.</citation>
    <PMID>32092748</PMID>
  </reference>
  <reference>
    <citation>Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond). 2020 Mar;20(2):124-127. doi: 10.7861/clinmed.2019-coron. Epub 2020 Mar 5. Review.</citation>
    <PMID>32139372</PMID>
  </reference>
  <reference>
    <citation>Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care. 2020 Mar 16;24(1):91. doi: 10.1186/s13054-020-2818-6.</citation>
    <PMID>32178711</PMID>
  </reference>
  <reference>
    <citation>Plantone D, Koudriavtseva T. Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. Clin Drug Investig. 2018 Aug;38(8):653-671. doi: 10.1007/s40261-018-0656-y. Review.</citation>
    <PMID>29737455</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istinye University</investigator_affiliation>
    <investigator_full_name>Mehmet Mahir Ozmen</investigator_full_name>
    <investigator_title>Professor of Surgery, Department of Surgery</investigator_title>
  </responsible_party>
  <keyword>Hydroxychloroquine</keyword>
  <keyword>coronavirus</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>healthcare professional</keyword>
  <keyword>outbreak</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

